Broadly neutralizing monoclonal #antibodies against #influenza A viruses: current #insights and future directions
Abstract Monoclonal antibodies (mAbs) have become attractive tools for both the treatment and prevention of influenza A viruses due to their ability to target several viral components, which confers broad therapeutic potential. Advances in biotechnology, such as hybridoma technology , phage display technology , B cell immortalization , and artificial intelligence (Al)-driven antibody design, have significantly accelerated the development of effective mAbs. Clinical trials have shown that mAbs can improve clinical outcomes particularly in high-risk and immunocompromised populations by lowering viral loads and reducing disease severity. However, high production costs, the need for intravenous administration , and the risk of viral escape mutations are some of the obstacles to widespread clinical adoption. Post-marketing surveillance serves as a valuable source of information regarding safety, real-world effectiveness, and patterns of resistance. Broadly neutralizing antibodies (bnA...